Semax Protocol
ACTH-fragment analog studied in Russian research literature for cognitive and neuroprotective effects.
- Cycle
- 4–8 weeks
Niveau de preuve : Investigationnel / théorique
Principalement des données précliniques ou des données humaines très limitées — un raisonnement fondé sur le mécanisme plutôt qu’un effet clinique démontré. À considérer comme investigationnel.
Preuves humaines : Human trials exist primarily within Russian research literature (including for stroke-recovery contexts); independent replication outside that literature is limited.
Preuves animales : Rodent BDNF and neuroprotection studies.
Introduction et mécanisme d'action
ACTH-fragment analog studied in Russian research literature for cognitive and neuroprotective effects.
Synthetic fragment of ACTH(4-10) with an added tripeptide extension; studied for increasing BDNF (brain-derived neurotrophic factor) expression, a mechanism linked to neuroplasticity and cognitive research.
Récepteurs/cibles : No confirmed classical receptor — proposed BDNF/neurotrophin-pathway modulation
Domaines d'intérêt pour la recherche
- Cognitive research
- Neuroprotection studies
Bénéfices rapportés dans la recherche
- Cognitive research
- Neuroprotection studies
Plage de dosage rapportée dans la recherche
Les chiffres ci-dessous sont cités à partir de la littérature de recherche publiée et de références de protocoles — ils décrivent ce qui a été étudié, et non une prescription ou instruction personnelle.
Plage rapportée : 250–500 mcg
Fréquence rapportée : 1× daily, intranasal
Durée de cycle rapportée : 4–8 weeks
Escalade et entretien : A dedicated weekly escalation and maintenance schedule specific to this peptide has not yet been published here — follow the dose range and frequency above, titrating conservatively from the low end, and consult a physician before adjusting.
Effets secondaires
- Nasal irritation (intranasal route)
- Headache (anecdotal)
Contre-indications
- Pregnancy
- Seizure disorder (theoretical concern given CNS-active mechanism)
Interactions médicamenteuses
- Not well characterized in controlled human trials
Sécurité
- No meaningful human safety database outside Russian research literature
- Independent international replication is limited
Most clinical use and literature originates from Russian research contexts; not FDA/EMA approved.
Résultats attendus et comparaison
Semax is studied primarily for cognitive/neuroprotective effects, while Selank is studied primarily for anxiolytic effects — the Selank+Semax Blend combines both research angles into one product, though combination-specific trials for that blend do not exist.